Article

Factors associated with changes in night-driving visual performance evaluated

Studies with a night-driving simulator (NDS) found that changes in night-driving performance were associated strongly with the type of treatment used to perform LASIK, and that wavefront-guided procedures were correlated with better performance. The study involved 59 patients (98 eyes) who were tested preoperatively and 6 months postoperatively with the NDS, set to simulate nighttime driving on a rural road at 55 miles per hour, with and without glare.

Studies with a night-driving simulator (NDS) found that changesin night-driving performance were associated strongly with thetype of treatment used to perform LASIK, and thatwavefront-guided procedures were correlated with betterperformance. The study involved 59 patients (98 eyes) who weretested preoperatively and 6 months postoperatively with the NDS,set to simulate nighttime driving on a rural road at 55 miles perhour, with and without glare.

Ret. U.S. Navy Capt. Steven C. Schallhorn, MD, San Diego,reported the results of the study, which included an analysis ofvariance of the influence of age, gender, preoperativecharacteristics such as refraction and pupil diameter, treatmentwith wavefront or conventional approaches, and postoperativefeatures such as refraction, change in best-corrected visualacuity, and contrast acuity, glare, and halo.

"We found no differences in the change in performance of eachindividual with respect to the type of conventional laser used,or the road hazard that was tested, or the eye that was tested,whether it be left or right," Dr. Schallhorn said. For analysis,data were pooled into detection and identification tasks, eachperformed with and without glare.

Overall, a slight decrease in night-driving performance was foundfor both detection and identification tasks, with and withoutglare, Dr. Schallhorn said. Significant variation existed amongthe patients, however.

Among the variables, the ablation profile was the predominantfactor explaining most of the variability of results in detectiontasks; change in glare symptoms at night and in halos also werepredictive. Change in contrast had a slight influence. Foridentification tasks, the ablation profile was again the dominantfactor, and change in glare symptoms also was significant. Changein contrast sensitivity proved to be a more significant factorfor these tasks than for those involving detection.

To examine the effect of the ablation profile more closely,results were correlated with a significant decrease innight-driving performance. About 30% of the conventionallytreated patients had a significant loss versus 0% to 3% of thosetreated with wavefront, Dr. Schallhorn said. No significantcorrelation was found between pupil size and changes in drivingperformance.

Although the influence of the ablation profile on change onnight-vision symptoms could be related to a lower incidence ofhigher-order aberrations with wavefront treatment, surgeryperformed with a femtosecond laser also may have had an impact,Dr. Schallhorn said, as patients treated with this device wereincluded in this group.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.